Begin main content

CADTH pan-Canadian Oncology Drug Review

The pan-Canadian Oncology Drug Review (pCODR) is an evidence-based, cancer drug review process.

The pCODR process is designed to bring consistency and clarity to the assessment of cancer drugs by reviewing clinical evidence, cost-effectiveness, and patient perspectives, and using this information to make recommendations to Canada's provinces and territories (except Quebec) in guiding their drug funding decisions.

Drug Review Updates

Nivolumab (Opdivo) for Advanced or Metastatic Hepatocellular Carcinoma
(Open for Feedback on Recommendation until October 19, 2018)

Pertuzumab-Trastuzumab (Perjeta-Herceptin) Combo Pack for Early Breast Cancer 
(Open for Feedback on Recommendation until October 19, 2018)

Bevacizumab (Mvasi) for Metastatic Colorectal Cancer / Non-Small Cell Lung Cancer Biosimilar
(Open for Input on Submission until October 18, 2018)

Venetoclax (Venclexta) in combo Rituximab for Chronic Lymphocytic Leukemia
(Pending Submission as of September 25, 2018)

Crizotinib (Xalkori) for ROS1-Positive Non-Small Cell Lung Cancer
(Pending Submission as of August 29, 2018)

Find a Drug Review